A Peptide Vaccine (PEP-CMV) for the Treatment of Pediatric Patients with Newly Diagnosed High-Grade Glioma and Diffuse Intrinsic Pontine Glioma, or Recurrent, Refractory, or Progressive Medulloblastoma

Inclusion Criteria

• STRATUM I PATIENTS WITH RECURRENT/PROGRESSIVE MEDULLOBLASTOMA: Patients must be ≥ 3 and ≤ 39 years of age at the time of study enrollment
• STRATUM I PATIENTS WITH RECURRENT/PROGRESSIVE MEDULLOBLASTOMA: Patients must have a diagnosis of medulloblastoma that is recurrent, progressive or refractory. All patients must have histological verification of a medulloblastoma, at original diagnosis or relapse * Patients must have measurable disease defined as a lesion that can be measured in two perpendicular diameters on MRI
• STRATUM I PATIENTS WITH RECURRENT/PROGRESSIVE MEDULLOBLASTOMA: Patients with M+ disease are eligible
• STRATUM I PATIENTS WITH RECURRENT/PROGRESSIVE MEDULLOBLASTOMA: Karnofsky ≥ 50% for patients > 16 years of age or Lansky ≥ 50 for patients ≤ 16 years of age. Patients who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score
• STRATUM I PATIENTS WITH RECURRENT/PROGRESSIVE MEDULLOBLASTOMA: Patients must have received prior disease-directed therapy including RT for their initial diagnosis of medulloblastoma unless patients are less than 4 years of age at the time of enrollment. * For those less than 4 years of age at the time of enrollment, prior disease directed therapy does not have to include prior RT * Patients must have had their last fraction of: ** Craniospinal irradiation (CSI), total body irradiation or radiation to ≥ 50% of pelvis > 3 months prior to enrollment ** Focal RT > 4 weeks prior to enrollment
• STRATUM I PATIENTS WITH RECURRENT/PROGRESSIVE MEDULLOBLASTOMA: Patients must have received their last dose of myelosuppressive anticancer therapy at least 21 days prior to enrollment
• STRATUM I PATIENTS WITH RECURRENT/PROGRESSIVE MEDULLOBLASTOMA: Patients must have received their last dose of any immunotherapy agents at least 30 days prior to enrollment
• STRATUM I PATIENTS WITH RECURRENT/PROGRESSIVE MEDULLOBLASTOMA: Patients must have received their last dose of non-myelosuppressive anticancer agents at least 7 days prior to study enrollment
• STRATUM I PATIENTS WITH RECURRENT/PROGRESSIVE MEDULLOBLASTOMA: Patients must have received their last dose of any antibodies at least 21 days prior to enrollment
• STRATUM I PATIENTS WITH RECURRENT/PROGRESSIVE MEDULLOBLASTOMA: Patients must have received their last dose of hematopoietic growth factors at least 14 days prior to enrollment for a long-acting growth factor (e.g. pegfilgrastim) or 7 days prior to enrollment for short-acting growth factor
• STRATUM I PATIENTS WITH RECURRENT/PROGRESSIVE MEDULLOBLASTOMA: At least 90 days must have elapsed after an autologous stem cell infusion
• STRATUM I PATIENTS WITH RECURRENT/PROGRESSIVE MEDULLOBLASTOMA: ANC (absolute neutrophil count) ≥ 1000/µl
• STRATUM I PATIENTS WITH RECURRENT/PROGRESSIVE MEDULLOBLASTOMA: Platelets ≥ 100,000/µl (may be supported)
• STRATUM I PATIENTS WITH RECURRENT/PROGRESSIVE MEDULLOBLASTOMA: Hemoglobin > 8 g/dL. (may be supported)
• STRATUM I PATIENTS WITH RECURRENT/PROGRESSIVE MEDULLOBLASTOMA: Creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70ml/min/1.73 m^2 or a serum creatinine based on age/gender as follows: * 2 to < 6 years: Maximum serum creatinine 0.8 mg/dL (male and female) * 6 to < 10 years: Maximum serum creatinine 1 mg/dL (male and female) * 10 to < 13 years: Maximum serum creatinine 1.2 mg/dL (male and female) * 13 to < 16 years: Maximum serum creatinine 1.5 mg/dL (male), 1.4 mg/dL (female) * ≥ 16 years: Maximum serum creatinine 1.7 mg/dL (male), 1.4 mg/dL (female)
• STRATUM I PATIENTS WITH RECURRENT/PROGRESSIVE MEDULLOBLASTOMA: Total bilirubin ≤ 1.5 times institutional upper limit of normal (ULN)
• STRATUM I PATIENTS WITH RECURRENT/PROGRESSIVE MEDULLOBLASTOMA: Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) ≤ 3 times institutional upper limit of normal
• STRATUM I PATIENTS WITH RECURRENT/PROGRESSIVE MEDULLOBLASTOMA: Alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) ≤ 3 times institutional upper limit of normal
• STRATUM I PATIENTS WITH RECURRENT/PROGRESSIVE MEDULLOBLASTOMA: Patients with neurological deficits should have deficits that are stable for a minimum of 2 weeks prior to enrollment
• STRATUM I PATIENTS WITH RECURRENT/PROGRESSIVE MEDULLOBLASTOMA: Patients with current seizure disorders may be enrolled if seizures are well-controlled on antiepileptic therapies
• STRATUM I PATIENTS WITH RECURRENT/PROGRESSIVE MEDULLOBLASTOMA: Patients of childbearing or child-fathering potential must be willing to use a medically acceptable form of birth control, which includes abstinence, while being treated on this study and for 3 months after drug cessation
• STRATUM I PATIENTS WITH RECURRENT/PROGRESSIVE MEDULLOBLASTOMA: Signed informed consent according to institutional guidelines must be obtained prior to enrollment
• STRATUM II PATIENTS WITH NEWLY DIAGNOSED HIGH GRADE GLIOMAS (HGG) AND STRATUM III NEWLY DIAGNOSED DIPG: Patients must be ≥ 3 and ≤ 39 years of age at the time of study enrollment
• STRATUM II PATIENTS WITH NEWLY DIAGNOSED HGG AND STRATUM III NEWLY DIAGNOSED DIPG: * Stratum II: Patients must have histologically confirmed, newly-diagnosed HGG ** Patients with a newly-diagnosed HGG must enroll within 6 weeks of their final dose of standard RT with or without chemotherapy ** Patients with primary spinal cord tumors are eligible * Stratum III: Patients with a newly-diagnosed biopsied or non-biopsied DIPG ** Patients with a radiographically typical DIPG, defined as a tumor with a pontine epicenter and diffuse involvement of more than 2/3 of the pons, are eligible without histologic confirmation ** Patients with brainstem lesions that do not meet these radiographic criteria will be eligible if there is histologic confirmation of an infiltrating astrocytoma World Health Organization (WHO) grades 2-4
• STRATUM II PATIENTS WITH NEWLY DIAGNOSED HGG AND STRATUM III NEWLY DIAGNOSED DIPG: Patients with M+ disease are eligible
• STRATUM II PATIENTS WITH NEWLY DIAGNOSED HGG AND STRATUM III NEWLY DIAGNOSED DIPG: Karnofsky >= 50 for patients > 16 years of age and Lansky >= 50 for patients =< 16 years of age. Patients who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score
• STRATUM II PATIENTS WITH NEWLY DIAGNOSED HGG AND STRATUM III NEWLY DIAGNOSED DIPG: Patients must have received no prior therapy other than surgery, RT, chemotherapy during RT and/or steroids (dexamethasone with goal to wean dexamethasone throughout protocol therapy) * Patients with a newly diagnosed HGG or DIPG must enroll within 6 weeks of their final dose of standard of care RT with or without chemotherapy
• STRATUM II PATIENTS WITH NEWLY DIAGNOSED HGG AND STRATUM III NEWLY DIAGNOSED DIPG: Patients with HGG or DIPG are permitted, but not required, to have received chemotherapy during radiation. Bevacizumab is permitted prior to enrollment in patients with DIPG or HGG. Patients must have received their last dose of bevacizumab at least 14 days prior to enrollment
• STRATUM II PATIENTS WITH NEWLY DIAGNOSED HGG AND STRATUM III NEWLY DIAGNOSED DIPG: * For HGG patients: ** Patients must have received RT at a standard dose of 54-59.4 gray (Gy) in 1.8 Gy fractions for approximately 6 weeks with an acceptable variance of 10%. Radiation therapy must have begun no later than 42 days after the date definitive surgery * For patients with DIPG: ** Patients must have received RT at a standard dose of 54 Gy in 1.8 Gy daily fractions for approximately 6 weeks with an acceptable variance rate of 10%. RT must have begun no later than 42 days after the date of radiographic diagnosis or biopsy * For patients with spinal cord HGG: ** Patients must have received RT at a standard dose of 45-54 Gy in 1.8 Gy fractions for approximately 6-7 weeks with an acceptable variance of 10% * For patients with metastatic disease: ** Patients may have received standard dose CSI
• STRATUM II PATIENTS WITH NEWLY DIAGNOSED HGG AND STRATUM III NEWLY DIAGNOSED DIPG: ANC (absolute neutrophil count) ≥ 1000/µl
• STRATUM II PATIENTS WITH NEWLY DIAGNOSED HGG AND STRATUM III NEWLY DIAGNOSED DIPG: Platelets ≥ 100,000/µl (may be supported)
• STRATUM II PATIENTS WITH NEWLY DIAGNOSED HGG AND STRATUM III NEWLY DIAGNOSED DIPG: Hemoglobin > 8 g/dL. (may be supported)
• STRATUM II PATIENTS WITH NEWLY DIAGNOSED HGG AND STRATUM III NEWLY DIAGNOSED DIPG: Creatinine clearance or radioisotope GFR >= 70ml/min/1.73 m^2 or a serum creatinine based on age/gender as follows: * 2 to < 6 years: Maximum serum creatinine 0.8 mg/dL (male and female) * 6 to < 10 years: Maximum serum creatinine 1 mg/dL (male and female) * 10 to < 13 years: Maximum serum creatinine 1.2 mg/dL (male and female) * 13 to < 16 years: Maximum serum creatinine 1.5 mg/dL (male), 1.4 mg/dL (female) * ≥ 16 years: Maximum serum creatinine 1.7 mg/dL (male), 1.4 mg/dL (female)
• STRATUM II PATIENTS WITH NEWLY DIAGNOSED HGG AND STRATUM III NEWLY DIAGNOSED DIPG: Total bilirubin ≤ 1.5 times institutional ULN
• STRATUM II PATIENTS WITH NEWLY DIAGNOSED HGG AND STRATUM III NEWLY DIAGNOSED DIPG: AST(SGOT) ≤ 3 times institutional upper limit of normal
• STRATUM II PATIENTS WITH NEWLY DIAGNOSED HGG AND STRATUM III NEWLY DIAGNOSED DIPG: ALT (SGPT) ≤ 3 times institutional upper limit of normal
• STRATUM II PATIENTS WITH NEWLY DIAGNOSED HGG AND STRATUM III NEWLY DIAGNOSED DIPG: Patients with neurological deficits should have deficits that are stable for a minimum of 1 week prior to enrollment
• STRATUM II PATIENTS WITH NEWLY DIAGNOSED HGG AND STRATUM III NEWLY DIAGNOSED DIPG: Patients of childbearing or child-fathering potential must be willing to use a medically acceptable form of birth control, which includes abstinence, while being treated on this study and for 3 months after drug cessation
• STRATUM II PATIENTS WITH NEWLY DIAGNOSED HGG AND STRATUM III NEWLY DIAGNOSED DIPG: Signed informed consent according to institutional guidelines must be obtained prior to enrollment

Exclusion Criteria

• ALL STRATA: Pregnant or breast-feeding women will not be entered on this study due to known or unknown risks of fetal and teratogenic adverse events as seen in animal/human studies. Pregnancy tests must be obtained in girls who are post-monarchal. Males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method
• ALL STRATA: Patients of childbearing or child fathering potential must be willing to use a medically acceptable form of birth control, which includes abstinence, while being treated on this study and for 3 months after drug cessation
• ALL STRATA: Active infection requiring treatment
• ALL STRATA: Patients with malignancy related to human immunodeficiency virus (HIV) or solid organ transplant: known history of HIV, hepatitis B virus (HBV) surface antigen positivity or positive hepatitis C virus (HCV) antibody are not eligible. Viral testing is not required unless clinically indicated in patients without a known history
• ALL STRATA: Known immunosuppressive disease
• ALL STRATA: Patients with active renal, cardiac (congestive cardiac failure, myocardial infarction, myocarditis), or moderate to severe pulmonary problems generally defined by need for medical intervention (e.g., oxygen, medications) and/or limiting activities of daily living (generally Common Terminology Criteria for Adverse Events [CTCAE] grade 2 or higher) or shortness of breath with limited exertion are not eligible. Pulmonary conditions include (but are not limited to) chronic obstructive pulmonary disease (COPD), asthma, and hemi-pneumectomy
• ALL STRATA: Patients receiving concomitant immunosuppressive agents for medical conditions; inhaled corticosteroids for asthma are allowed
• ALL STRATA: Patients receiving concomitant tumor-directed therapy
• ALL STRATA: Patients receiving any other investigational drug therapy
• ALL STRATA: Patients on dexamethasone > 0.1 mg/Kg/day up to maximum dose of 4 mg/day or equivalent
• ALL STRATA: Patients with any clinically significant unrelated systemic illness (serious infections or significant cardiac, pulmonary, hepatic or other organ dysfunction)
• ALL STRATA: Patients with inability to return for follow-up visits or obtain follow-up studies required to assess toxicity to therapy
• ALL STRATA: Patients at high risk for imminent neurologic decline due to extensive bulk disease, midline shift, or herniation on MRI. These patients should be discussed with the study chairs